key: cord-0821897-xwvvmdes
authors: Willems, Loes H.; Nagy, Magdolna; Ten Cate, Hugo; Spronk, Henri M. H.; Jacobs, Lotte M. C.; Kranendonk, Josephine; van Leeuwen, Maaike; Meijer, Danielle; Middeldorp, Saskia; Groh, Laszlo A.; Warlé, Michiel C.
title: ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
date: 2021-12-07
journal: Res Pract Thromb Haemost
DOI: 10.1002/rth2.12630
sha: 11b8f9cd003d5df3b0f80fe0dd3f7f7efa0c5360
doc_id: 821897
cord_uid: xwvvmdes

BACKGROUND: Vaccination is the leading approach in combatting the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. ChAdOx1 nCoV‐19 vaccination (ChAdOx1) has been linked to a higher frequency of rare thrombosis and thromboembolism. This study aimed to explore markers related to the blood coagulation system activation and inflammation, before and after ChAdOx1 vaccination. PATIENTS AND METHODS: An observational cohort study including 40 health care workers. Whole blood samples were collected before, and either 1 or 2 days after vaccination. Activated coagulation factors in complex with their natural inhibitors were determined by custom ELISAs, including thrombin:antithrombin (T:AT), kallikrein:C1‐esterase‐inhibitor (PKa:C1Inh), factor(F)IXa:AT, FXa:AT, FXIaAT, FXIa:alpha‐1‐antitrypsin (α1AT), FXIa:C1inh, and FVIIa:AT. Plasma concentrations of interleukin (IL)‐6 and IL‐18 were quantified via ELISA. Analyses were performed using Wilcoxon signed‐rank test. RESULTS: Levels of FVIIa:AT decreased with a median (IQR) of 707 (549–1028) pg/ml versus 598 (471–996) pg/ml, p = 0.01; and levels of IL‐6 increased, 4.0 (1.9–6.8) pg/ml versus 6.9 (3.6–12.2) pg/ml, p = 0.02, after vaccination. No changes were observed in T:AT, PKa:C1Inh, FIXa:AT, FXa:AT, FXIaAT, FXIa:α1AT, FXIa:C1inh, and IL‐18. CONCLUSION: ChAdOx1 leads to an inflammatory response with increased levels of IL‐6. We did not observe activation of the blood coagulation system 1–2 days following vaccination.

Thrombosis is a frequent complication in patients during the acute and recovery phase of the coronavirus disease 2019 (COVID-19). [1] [2] [3] [4] Reflecting this increased thrombotic risk, complexes of activated coagulation factors and their inhibitors were elevated in plasma of individuals with COVID-19. These factors similarly vary with disease severity. 5 Unpublished data from our group show that, ~3 months after COVID-19 infection, the same markers of blood coagulation system activation remain increased in 40%-50% of all patients, alongside elevated inflammatory cytokines [submitted for publication]. As novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to infect individuals worldwide, vaccination is the leading approach in mitigating this pandemic. By August 2021, four different COVID-19 vaccines have been approved by the European Medicines Agency. Among these, the ChAdOx1 nCoV-19 vaccine (ChAdOx1) of AstraZeneca, which has been shown to be safe and effective in randomized controlled trials. 6 Despite this evidence in favor of the use of ChAdOx1, the vaccination program was discontinued in several European countries because of observations of extensive thrombosis in atypical sites with associated thrombocytopenia occurring at a low frequency. 7 This manifestation, now known as vaccine-induced immune thrombotic thrombocytopenia (VITT), is associated with anti-platelet 4 antibodies activating platelets. 8, 9 Besides the rare occurrence of VITT, researchers have described a higher frequency of general thrombosis and thromboembolism in individuals recently vaccinated with ChAdOx1 when compared with individuals vaccinated with other COVID-19 vaccines 10 and compared with the general population. 11 This raises the question whether ChAdOx1 could induce activation of the blood coagulation system, comparable to the activation of the blood coagulation system by SARS-CoV-2 itself. This study aimed to explore changes in circulating biomarkers of the activated blood coagulation system and proinflammatory cytokines before and after ChAdOx1 vaccination.

An observational cohort study was performed including 40 health care workers of the Radboud University Medical Center Baseline demographics and clinical data regarding medical history and medication use were requested. Whole blood samples were collected prior to vaccination. A second whole blood sample collection was scheduled for either 1 or 2 days after vaccination, endeavoring to include equal numbers of participants in both groups and considering participants preferences for the day of second collection.

Whole blood samples were collected and processed to platelet-poor plasma by standard procedures. 12 

Forty health care workers, scheduled for the first dose of ChAdOx1 vaccination, were recruited by open invitation. One subject did not meet the in-and exclusion criteria and was replaced. Subjects were assessed for changes in circulating biomarkers of blood coagulation activation and proinflammatory cytokines, before and 1 or 2 days after exposure to ChAdOx1 vaccination. All participants were aged between 60 and 65 years, the mean body mass index was 26 kg/m 2 , and 20% of the subjects were male. Comorbidities, most frequently hypertension (22.5%) and cardiovascular disease (22.5%), were present in 65% of individuals. Nineteen subjects had their second blood sample collection 1 day after vaccination, and 21 subjects had their second blood sample collection 2 days after vaccination. No significant differences were established in baseline characteristics or medical history between the two groups (Table 1 ).

In vivo blood coagulation activity was measured and com- Binding of FVII to TF could have reduced the availability of FVIIa to bind to AT, its natural inhibitor, thus resulting in the observed decrease in levels of FVIIa:AT. However, a type I error cannot be excluded. We found no further evidence of extrinsic pathway activation as reflected by comparable levels of FIXa:AT, Fxa:AT, and T:AT, before and after ChAdOx1 vaccination.

All participants were followed for health complaints until 4 weeks after vaccination. Thirty-two (80%) of the subjects reported health complaints, including injection site tenderness, myalgia, headache, malaise, fever, chills, nausea, or diarrhea. All health complaints resolved within 4 days following vaccination with ChAdOx1.

No complications related to thrombosis or thromboembolism were reported.

This study had some limitations. All participants were aged 60-65 years, and the sample size was small, which limits the generalizability of the study results. Changes in markers related to blood coagulation system activation and inflammation were measured 24-48 h after vaccination. Our results, therefore, represent the immediate response of the blood coagulation and inflammatory system. In previous literature, the immediate inflammatory response following vaccination is measurable at 24 h after the trigger. 17 Coagulation system activation is related to inflammation and, more specific, to IL-6 release. 19 The onset of thrombosis and thromboembolism following ChAdOx1 vaccination usually occurs after the first 24 h. By measuring changes in markers related to blood coagulation system activation and inflammation at 24 and 48 h after vaccination, both the immediate inflammatory response and an eventually increasing trend in coagulation system activation, should be noticed. The 

occurrence of VITT, which is generally diagnosed 4 or more days after vaccination, was not studied. Also, not all possibilities for immediate blood coagulation activation were assessed, such as platelet aggregation, which was not altered in previous literature. 20

In conclusion, the current study found no evidence of immediate activation of the blood coagulation system 1-2 days following ChAdOx1 vaccination. ChAdOx1 leads to an inflammatory response with increased levels of IL-6, as seen previously with other types of vaccinations. The increase in IL-6, however, does not coincide with extrinsic pathway activation.

The authors thank Tjarda Tromp who provided assistance and support for the practical execution of this study, and Trix the Boer for assistance and coordination of the laboratory processes.

None. Abbreviations: α1AT, alpha-1-antitrypsin; C1Inh, C1-esterase-inhibitor; F, factor; IL, interleukin; IQR, interquartile range; Pka, kallikrein; T:AT, thrombin:antithrombin.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Incidence of venous thromboembolism in hospitalized patients with COVID-19

The prevalence of pulmonary embolism in patients with COVID-19 and respiratory decline: a three-setting comparison

Incidence of thrombotic complications and overall survival in hospitalized patients with COVID-19 in the second and first wave

Neutrophils and contact activation of coagulation as potential drivers of COVID-19

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2

Comparison of adverse drug reactions among four COVID-19 vaccines in Europe using the EudraVigilance database: thrombosis at unusual sites

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method

The plasma kallikrein-kinin system and risk of cardiovascular disease in men

IL-6 production following vaccination in pigs-an additional immune response parameter for assessing FMD vaccine efficacy? Vaccine

Whole blood profiling of bacillus Calmette-Guérin-induced trained innate immunity in infants identifies epidermal growth factor, IL-6, plateletderived growth factor-AB/BB, and natural killer cell activation

Changes in TNF and IL-6 production after diphtheria toxoid vaccination: drug modulation of the cytokine levels

Influenza vaccination induces NK-cell-mediated type-II IFN response that regulates humoral immunity in an IL-6-dependent manner

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity

Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine does not alter platelet aggregation